Connect to other sites within the UBM Medica Network
ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.
Clinical Trial Participation Low in Lung, Colorectal Cancers
Only 14% of newly diagnosed lung or colorectal cancer patients reported discussing clinical trial participation with their physician, and fewer participated.
Thymidylate Synthase Predicts Response to Chemo in NSCLC
A new study suggests that expression of the enzyme thymidylate synthase can be used as a predictive marker for lung cancer patients undergoing chemotherapy.
ASCO Endorses Lung Cancer Guidelines for Molecular Testing
MAGE-A3 Lung Cancer Vaccine Provides No Benefit Over Placebo
The MAGRIT trial showed no benefit with the recMAGE-A3 + AS15 cancer immunotherapeutic compared with placebo in completely resected, MAGE-A3-positive NSCLC.
Data Backs CT Lung Screening in More High-Risk Patients
NCCN Group 2 high-risk patients to benefit from CT lung screening, study says.
After Lung Cancer Progression, Gefitinib Provides No Benefit
Continuing gefitinib after acquiring resistance to the TKI adds no clinical benefit in patients with EGFR-positive non-small-cell lung cancer, according to trial results presented at the 2014 ESMO Congress.
Thoracic RT Improves Long-Term Survival in Extensive-Stage SCLC
Adding thoracic radiotherapy to chemotherapy and prophylactic cranial irradiation improved 2-year survival in extensive-stage small-cell lung cancer patients.
Oncogenic Drivers in Lung Cancer
From the 2014 ASCO Annual Meeting, this internationally renowned lung cancer expert discusses oncogenic driver mutations in lung cancer.
ASCO: Current and Upcoming Lung Cancer Research
Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.
ASCO: Controversies in the Treatment of Mesothelioma of the Pleura
In this exclusive video, Dr. Harvey Pass discusses surgery in mesothelioma of the pleura and other areas of disagreement.
ASCO: Chemotherapy Key Part of Curative Lung Cancer Therapies
As part of our coverage of the 2014 ASCO Annual Meeting, we discuss chemotherapy's curative role in treating lung cancer.
Combination Therapies for Lung Cancer
As part of our coverage of the AACR Annual Meeting, we discuss combination therapies and new research in the treatment of lung cancer.
Oncogenes Driving Squamous Cell Lung Carcinoma
In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.
Lung Cancer Prevention and Screening
In this interview we discuss lung cancer prevention, the recent low-dose CT screening recommendations from the USPSTF, hurdles in preventing the disease, and more.
By clicking Accept, you agree to become a member of the UBM Medica Community.